Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Feb 2nd based on HKEx daily reports.</li>
<li>In the past 7 days, the top 3 companies that repurchased the most shares from the market were AIA (1299 HK), Xiaomi (1810 HK), Kuaishou Technology (1024 HK).</li>
<li>In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Meituan (3690 HK), AIA (1299 HK).</li>
</ul>


We analyze statistics on top repurchases over one week, one month, one quarter and one year periods ended on Feb 2nd based on HKEx daily reports.
In the past 7 days, the top 3 companies that repurchased the most shares from the market were AIA (1299 HK), Xiaomi (1810 HK), Kuaishou Technology (1024 HK).
In the past 30 days, the top 3 companies that repurchased the most shares from the market were Tencent (700 HK), Meituan (3690 HK), AIA (1299 HK).


Hong Kong Buybacks Weekly (Feb 2nd): AIA, Xiaomi, Kuaishou Technology

Blue Lotus China New Economy Research, Blue Lotus Research Institute

Eric Wen

Blue Lotus China New Economy Research

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>1810 HK：Samsung Galaxy S24 pre-orders in South Korea reach nearly 1.2 million  units, with a potential of 36 million units for the year(+)</li>
<li>LKNCY: Luckin Coffee reduced US$400mn registered capital, which may intend to comply with the new company law(/)</li>
<li>2269 HK: US Congress wants to ban BGI and possibly Wuxi AppTec from doing business in US (-)</li>
</ul>


1810 HK：Samsung Galaxy S24 pre-orders in South Korea reach nearly 1.2 million  units, with a potential of 36 million units for the year(+)
LKNCY: Luckin Coffee reduced US$400mn registered capital, which may intend to comply with the new company law(/)
2269 HK: US Congress wants to ban BGI and possibly Wuxi AppTec from doing business in US (-)


[Blue Lotus Daily]:ACMR/300750 SZ/DIDI/NIO/1810 HK/TCOM/LKNCY/2269 HK

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Jan 19th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period. </li>
<li>We highlight short changes in HSBC, China Mobile, Shk Ppt, Wuxi Bio, Kuaishou, Li Auto.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Jan 19th.
Top short increases and decreases were tabulated for one week and four week period. 
We highlight short changes in HSBC, China Mobile, Shk Ppt, Wuxi Bio, Kuaishou, Li Auto.


HK Short Interest Weekly: HSBC, China Mobile, Shk Ppt, Wuxi Bio, Kuaishou, Li Auto

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>We expected a blandiloquent but bletcherous bump for <a href="https://www.smartkarma.com/entities/t-k-toka-co-ltd" target="_blank" data-smartkarma-citation="entities:18678:1" rel="noopener">T&amp;K Toka Co Ltd (4636 JP)</a>.  We got bletcherous.</li>
<li>With the Hang Seng Index dipping below the 15,000 mark earlier this week, time to dust off some old school perspective with Benjamin Graham's Net Nets.</li>
<li>JIC CEO Yokoo reckons the <a href="https://www.smartkarma.com/entities/jsr-corp" target="_blank" data-smartkarma-citation="entities:17620:1" rel="noopener">JSR Corp (4185 JP)</a> deal to be done by March-end. Language is vague. If that means to start by then, that's still 30% annualised.</li>
</ul>


We expected a blandiloquent but bletcherous bump for T&amp;K Toka Co Ltd (4636 JP).  We got bletcherous.
With the Hang Seng Index dipping below the 15,000 mark earlier this week, time to dust off some old school perspective with Benjamin Graham's Net Nets.
JIC CEO Yokoo reckons the JSR Corp (4185 JP) deal to be done by March-end. Language is vague. If that means to start by then, that's still 30% annualised.


Last Week in Event SPACE: T&K TOKA, Liquidated HK Stocks, JSR, Orecorp, Brilliance Auto, Hollysys

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/samsung-biologics-co-ltd" target="_blank" data-smartkarma-citation="entities:22932:1" rel="noopener">Samsung Biologics (207940 KS)</a> reported 11% YoY growth in revenue to KRW1.07 trillion in 4Q23 driven by the ramp-up of operation of its Plant 4 and robust sales backlog.</li>
<li>The company closed 2023 with record high revenue and operating profit, bucking the weakening trend in overall global CDMO sector.</li>
<li>The outlook remains strong, with resilient business performance expected to drive a 10–15% annual growth in revenue for 2024.</li>
</ul>



Samsung Biologics (207940 KS) reported 11% YoY growth in revenue to KRW1.07 trillion in 4Q23 driven by the ramp-up of operation of its Plant 4 and robust sales backlog.
The company closed 2023 with record high revenue and operating profit, bucking the weakening trend in overall global CDMO sector.
The outlook remains strong, with resilient business performance expected to drive a 10–15% annual growth in revenue for 2024.


Samsung Biologics (207940 KS): Stellar Performance in 4Q23; Outlook Remains Strong

China

WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland.  We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions. 

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Wuxi Biologics (2269 HK)

Hong Kong Buybacks Weekly (Feb 2nd): AIA, Xiaomi, Kuaishou Technology

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were AIA (1299 HK),...

Ke Yan, CFA, FRM

[Blue Lotus Daily]:ACMR/300750 SZ/DIDI/NIO/1810 HK/TCOM/LKNCY/2269 HK

Samsung Galaxy S24 pre-orders in South Korea reach nearly 1.2 million units; Luckin Coffee reduces registered capital by US$400mn; US Congress...

Blue Lotus Research Institute

HK Short Interest Weekly: HSBC, China Mobile, Shk Ppt, Wuxi Bio, Kuaishou, Li Auto

We analyzed the latest HK SFC report for aggregate short position as of Jan 19th and highlight short interest changes in HSBC, China Mobile, Shk...

Ke Yan, CFA, FRM

Last Week in Event SPACE: T&K TOKA, Liquidated HK Stocks, JSR, Orecorp, Brilliance Auto, Hollysys

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

David Blennerhassett

Samsung Biologics (207940 KS): Stellar Performance in 4Q23; Outlook Remains Strong

Samsung Biologics reported 11% YoY revenue growth in 4Q23, driven by Plant 4 operations and strong sales backlog. Resilient business performance...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hong Kong Buybacks Weekly (Feb 2nd): AIA, Xiaomi, Kuaishou Technology

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were AIA (1299 HK),...

Ke Yan, CFA, FRM

[Blue Lotus Daily]:ACMR/300750 SZ/DIDI/NIO/1810 HK/TCOM/LKNCY/2269 HK

​Samsung Galaxy S24 pre-orders in South Korea reach nearly 1.2 million units; Luckin Coffee reduces registered capital by US$400mn; US Congress...

Blue Lotus Research Institute

HK Short Interest Weekly: HSBC, China Mobile, Shk Ppt, Wuxi Bio, Kuaishou, Li Auto

We analyzed the latest HK SFC report for aggregate short position as of Jan 19th and highlight short interest changes in HSBC, China Mobile, Shk...

Ke Yan, CFA, FRM

Last Week in Event SPACE: T&K TOKA, Liquidated HK Stocks, JSR, Orecorp, Brilliance Auto, Hollysys

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

David Blennerhassett

Samsung Biologics (207940 KS): Stellar Performance in 4Q23; Outlook Remains Strong

​Samsung Biologics reported 11% YoY revenue growth in 4Q23, driven by Plant 4 operations and strong sales backlog. Resilient business performance...

Tina Banerjee

Samsung Galaxy S24 pre-orders in South Korea reach nearly 1.2 million units; Luckin Coffee reduces registered capital by US$400mn; US Congress...

Samsung Biologics reported 11% YoY revenue growth in 4Q23, driven by Plant 4 operations and strong sales backlog. Resilient business performance...